[Cardiovascular toxicity of some cancer agents (others than anthracyclines, fluoropyrimidines and trastuzumab)].
Many others cancer agents can lead to cardiovascular toxicity apart from anthracyclines, 5-fluorouracil, trastuzumab and ionizing radiations. Paclitaxel, high-dose cyclophosphamide and ifosfamide, mitomycin and irinotecan cardiotoxicity is unusual but for certain. Hormonal therapy is extensively used in breast and prostate cancers. Thromboembolic and cardiovascular events are increased by estrogens, synthetic progestatives and tamoxifene. Because of major toxicities related to intravenous interleukin-2, subcutaneous interleukin-2 regimens have been developed, allowing an improvement of cardiovascular tolerability. Interferon is less frequently associated with cardiotoxicity. Before treatment initiation, risk factors favouring cardiac toxicity should be evaluated. These risk factors can be related to the cancer agent, to the patient or to the tumour. Uncommon toxic events in general population can be more frequent in high risk patients. Therapeutic option can be influenced by these uncommon toxic events in high risk patients.
Saintigny
Pierre
P
Service d'Oncologie Médicale, Hôpital Avicenne, 125 route de Stalingrad, 93009 Bobigny. pierre.saintigny@avc.ap-hop-paris.fr
Chouahnia
Kader
K
Charniot
Jean-Christophe
JC
Breau
Jean-Luc
JL
D000970:Antineoplastic Agents / Q000009:adverse effects*; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects; D006321:Heart / Q000187:drug effects*; D006331:Heart Diseases / Q000139:chemically induced*; D006801:Humans; D007167:Immunotherapy / Q000009:adverse effects
D000970:Antineoplastic Agents; D018931:Antineoplastic Agents, Hormonal